154 related articles for article (PubMed ID: 26124352)
21. [Successful Administration of Regorafenib to a Metastatic Colon Cancer Patient with Impaired Performance Status by Reducing the Initial Dose].
Nishitai R; Manaka D; Kudo R; Mitsuoka E; Kanai S; Kanto S; Yoshino K; Hamasu SY; Konishi S; Yamashiro Y
Gan To Kagaku Ryoho; 2015 Jul; 42(7):871-3. PubMed ID: 26197753
[TBL] [Abstract][Full Text] [Related]
22. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
23. Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.
Myint ZW; Sen JM; Watts NL; Druzgal TJ; Nathan BR; Ward MD; Boyer JE; Fracasso PM
Clin Colorectal Cancer; 2014 Jun; 13(2):127-30. PubMed ID: 24461491
[No Abstract] [Full Text] [Related]
24. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
25. Regorafenib induced severe toxic hepatitis: characterization and discussion.
Sacré A; Lanthier N; Dano H; Aydin S; Leggenhager D; Weber A; Dekairelle AF; De Cuyper A; Gala JL; Humblet Y; Sempoux C; Van den Eynde M
Liver Int; 2016 Nov; 36(11):1590-1594. PubMed ID: 27500989
[TBL] [Abstract][Full Text] [Related]
26. [Tolerability and efficacy of regorafenib in patients with unresectable metastatic colorectal cancer].
Tanaka A; Sadahiro S; Suzuki T; Okada K; Saito G
Gan To Kagaku Ryoho; 2014 Oct; 41(10):1231-6. PubMed ID: 25335705
[TBL] [Abstract][Full Text] [Related]
27. Regorafenib in metastatic colorectal cancer.
Grothey A
Clin Adv Hematol Oncol; 2012 May; 10(5):324-5. PubMed ID: 22706543
[No Abstract] [Full Text] [Related]
28. Regorafenib for treatment of hepatocellular carcinoma.
Sherman M
Hepatology; 2018 Mar; 67(3):1162-1165. PubMed ID: 29059458
[No Abstract] [Full Text] [Related]
29. Investigation of Regorafenib-induced Hypothyroidism in Patients with Metastatic Colorectal Cancer.
Sugita K; Kawakami K; Yokokawa T; Mae Y; Toya W; Hagino A; Suzuki K; Suenaga M; Mizunuma N; Yamaguchi T; Hama T
Anticancer Res; 2015 Jul; 35(7):4059-62. PubMed ID: 26124355
[TBL] [Abstract][Full Text] [Related]
30. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial.
Eisen T; Joensuu H; Nathan PD; Harper PG; Wojtukiewicz MZ; Nicholson S; Bahl A; Tomczak P; Pyrhonen S; Fife K; Bono P; Boxall J; Wagner A; Jeffers M; Lin T; Quinn DI
Lancet Oncol; 2012 Oct; 13(10):1055-62. PubMed ID: 22959186
[TBL] [Abstract][Full Text] [Related]
31. Regorafenib. Metastatic colorectal cancer in treatment failure: may prolong survival by a few weeks.
Prescrire Int; 2014 Jan; 23(145):8-11. PubMed ID: 24516902
[TBL] [Abstract][Full Text] [Related]
32. Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations.
Grothey A
Clin Adv Hematol Oncol; 2015 Aug; 13(8):514-7. PubMed ID: 26351814
[No Abstract] [Full Text] [Related]
33. Reduced dose of salvage-line regorafenib monotherapy for metastatic colorectal cancer in Japan.
Hirano G; Makiyama A; Makiyama C; Esaki T; Oda H; Uchino K; Komoda M; Tanaka R; Matsushita Y; Mitsugi K; Shibata Y; Kumagai H; Arita S; Ariyama H; Kusaba H; Akashi K; Baba E
Anticancer Res; 2015 Jan; 35(1):371-7. PubMed ID: 25550574
[TBL] [Abstract][Full Text] [Related]
34. Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.
Quirino M; Rossi S; Schinzari G; Basso M; Strippoli A; Cassano A; Barone C
Medicine (Baltimore); 2017 Apr; 96(16):e6522. PubMed ID: 28422839
[TBL] [Abstract][Full Text] [Related]
35. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
[TBL] [Abstract][Full Text] [Related]
36. Regorafenib- associated panniculitis.
Chockalingam R; Aung P; Patel AB
Dermatol Online J; 2016 Jun; 22(6):. PubMed ID: 27617607
[TBL] [Abstract][Full Text] [Related]
37. Regorafenib as a single-agent in the treatment of patients with gastrointestinal tumors: an overview for pharmacists.
Rey JB; Launay-Vacher V; Tournigand C
Target Oncol; 2015 Jun; 10(2):199-213. PubMed ID: 25213039
[TBL] [Abstract][Full Text] [Related]
38. Regorafenib (Stivarga) for metastatic colorectal cancer and GIST.
Med Lett Drugs Ther; 2013 Apr; 55(1415):e36. PubMed ID: 23836345
[No Abstract] [Full Text] [Related]
39. Gastrointestinal Stromal Tumor in a Patient with Neurofibromatosis Type 1 That Was Successfully Treated with Regorafenib.
Fujimi A; Nagamachi Y; Yamauchi N; Tamura F; Kimura T; Miyajima N; Inomata H; Nishisato T; Yoshida M; Takada K; Kobayashi K; Kato J
Intern Med; 2019 Jul; 58(13):1865-1870. PubMed ID: 30918185
[TBL] [Abstract][Full Text] [Related]
40. Clinical Activity of Sunitinib and Regorafenib in Endometriosis.
Mir O; Ropert S; Morice P; Berveiller P
Mayo Clin Proc; 2019 Dec; 94(12):2591-2593. PubMed ID: 31806110
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
